| Abstract
| - The aim of this work was to develop lead pharmacodynamic hybrids, NO-sartans, possessing the characteristicsof a typical AT1-antagonist and of a “slow NO donor”, by addingNO-donor side chains to losartan. These new compounds, 2aand 2b, displayed vasorelaxing effects, due to the release ofNO, and antagonized the vasocontractile effects of angiotensinII, with potency values similar to that of losartan. In vivo, theantihypertensive effects of 2a were similar to those of losartanand captopril.
|
